[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588173":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":31,"centralContacts":37,"locations":46,"responsibleParty":165,"collaborators":31,"id":167,"slug":168,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":31,"eligibilityCriteria":173,"healthyVolunteers":169,"sex":174,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":31,"studyType":180,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":49,"whyStopped":31,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"JHM BioPharma (Tonghua) Co. , Ltd.","NETWORK",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Eveotox","EXPERIMENTAL","Eveotox, 20 Units, divided into five injections into the glabellar area. Administered in double-blind fashion at cycle 1 followed by up to 3 open-label cycles.",[13],"Biological: Rcombinant botulinum toxin type A for injection（Eveotox)",{"label":15,"type":16,"description":17,"interventionNames":18},"OnabotulinumtoxinA (Botox )","ACTIVE_COMPARATOR","Botox,20 Units, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units).",[19],"Biological: OnabotulinumtoxinA (Botox)",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo","PLACEBO_COMPARATOR","Placebo, will be administered in double-blind fashion during treatment cycle 1 only, followed by up to 3 of Eveotox(20 Units)",[25],"Biological: Placebo",[27,32,35],{"type":28,"name":29,"description":29,"armGroupLabels":30,"otherNames":31},"BIOLOGICAL","Rcombinant botulinum toxin type A for injection（Eveotox)",[9],null,{"type":28,"name":33,"description":33,"armGroupLabels":34,"otherNames":31},"OnabotulinumtoxinA (Botox)",[15],{"type":28,"name":21,"description":21,"armGroupLabels":36,"otherNames":31},[21],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":31,"email":42},"Danhua Lin","CONTACT","15811460241","danhua.lin@jhm-biopharma.com",{"name":44,"role":40,"phone":31,"phoneExt":31,"email":45},"Lei Wang","lei.wang@jhm-biopharma.com",[47,60,65,70,79,88,93,102,111,120,129,133,142,151,160],{"facility":48,"status":49,"city":50,"state":51,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":31},"Peking Union Medical College Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.39723,39.9075,{"lat":58,"lon":57},{"facility":61,"status":49,"city":50,"state":51,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":62,"geoPoint":64,"contacts":31},"Peking University First Hospital",{"type":55,"coordinates":63},[57,58],{"lat":58,"lon":57},{"facility":66,"status":49,"city":50,"state":51,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":67,"geoPoint":69,"contacts":31},"Peking University Third Hospital",{"type":55,"coordinates":68},[57,58],{"lat":58,"lon":57},{"facility":71,"status":49,"city":72,"state":73,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":74,"geoPoint":78,"contacts":31},"The First Affiliated Hospital of Chongqing Medical University","Chongqing","Chongqing Municipality",{"type":55,"coordinates":75},[76,77],106.55771,29.56026,{"lat":77,"lon":76},{"facility":80,"status":49,"city":81,"state":82,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":83,"geoPoint":87,"contacts":31},"The First Affiliated Hospital of Jinan University","Guangzhou","Guangdong",{"type":55,"coordinates":84},[85,86],113.25,23.11667,{"lat":86,"lon":85},{"facility":89,"status":49,"city":81,"state":82,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":90,"geoPoint":92,"contacts":31},"The Third Affiliated Hospital of Sun Yat-sen University",{"type":55,"coordinates":91},[85,86],{"lat":86,"lon":85},{"facility":94,"status":49,"city":95,"state":96,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":97,"geoPoint":101,"contacts":31},"The First Hospital of Hebei Medical University","Shijiazhuang","Hebei",{"type":55,"coordinates":98},[99,100],114.47861,38.04139,{"lat":100,"lon":99},{"facility":103,"status":49,"city":104,"state":105,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":106,"geoPoint":110,"contacts":31},"The Third Xiangya Hospital of Central South University","Changsha","Hunan",{"type":55,"coordinates":107},[108,109],112.97087,28.19874,{"lat":109,"lon":108},{"facility":112,"status":49,"city":113,"state":114,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":115,"geoPoint":119,"contacts":31},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou","Jiangsu",{"type":55,"coordinates":116},[117,118],117.28386,34.20442,{"lat":118,"lon":117},{"facility":121,"status":49,"city":122,"state":123,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":124,"geoPoint":128,"contacts":31},"Huashan Hospital, Fudan University","Shanghai","Shanghai Municipality",{"type":55,"coordinates":125},[126,127],121.45806,31.22222,{"lat":127,"lon":126},{"facility":130,"status":49,"city":131,"state":132,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":31,"geoPoint":31,"contacts":31},"Xianyang Hospital of Yan'an University","Xianyang","Shanxi",{"facility":134,"status":49,"city":135,"state":136,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":137,"geoPoint":141,"contacts":31},"West China Hospital, Sichuan University","Chengdu","Sichuan",{"type":55,"coordinates":138},[139,140],104.06667,30.66667,{"lat":140,"lon":139},{"facility":143,"status":49,"city":144,"state":145,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":146,"geoPoint":150,"contacts":31},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality",{"type":55,"coordinates":147},[148,149],117.17667,39.14222,{"lat":149,"lon":148},{"facility":152,"status":49,"city":153,"state":154,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":155,"geoPoint":159,"contacts":31},"Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University","Hangzhou","Zhejiang",{"type":55,"coordinates":156},[157,158],120.16142,30.29365,{"lat":158,"lon":157},{"facility":161,"status":49,"city":153,"state":154,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":162,"geoPoint":164,"contacts":31},"Zhejiang Provincial People's Hospital",{"type":55,"coordinates":163},[157,158],{"lat":158,"lon":157},{"type":166,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100588173","phase-3-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-for-injection-to-treat-moderate-to-severe-glabellar-lines-100588173",false,"NCT06937944","Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines","A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n* Male or female subjects who are between 18 to 65 years of age\n* Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale\n* Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale\n* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial\n\nExclusion Criteria:\n\n* Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug\n* Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening\n* Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety\n* Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period","ALL","18 Years","65 Years",{"count":178,"type":179},669,"ESTIMATED","INTERVENTIONAL",[182],"PHASE3","This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single\u002Frepeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.",[185],"Moderate to Severe Glabellar Lines",[185],"2025-08-25",{"date":189,"type":190},"2025-09-02","ACTUAL",{"date":192,"type":190},"2025-04-30",{"date":194,"type":179},"2026-08",{"name":5,"class":6},15]